SCHEMBL3704674

SCHEMBL3704674

CC(C)(C)OC(=O)N1CCN(c2ccc(NC(=O)n3cc4ccccc4c3)cc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.71
MAPT P10636 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 1/20 0.56
TSHR P16473 1/20 0.56
KMT2A Q03164 1/20 0.56
ALDH1A1 P00352 2/20 0.53
LMNA P02545 2/20 0.53
ESR2 Q92731 1/20 0.53
NPC1 O15118 1/20 0.53
NR2F2 P24468 1/20 0.53
HTT P42858 1/20 0.53
GPR119 Q8TDV5 3/20 0.53
JAK2 O60674 1/20 0.52
JAK3 P52333 1/20 0.52
CCNK O75909 1/20 0.49
CCNA2 P20248 1/20 0.49
CDK2 P24941 1/20 0.49
CCND3 P30281 1/20 0.49
CDK9 P50750 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704675 0.83 NAMPT (1.00) NAMPT
SCHEMBL3706432 0.81 NAMPT (0.54) NAMPTALDH1A1GPR119
SCHEMBL3256196 0.81 NAMPT (0.69) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL29037711 0.81 NAMPT (0.69) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL31034622 0.80 NAMPT (0.67) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5573222 0.79 MAPT (0.76) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL29803251 0.79 MAPT (0.69) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL13853617 0.79 NAMPT (0.66) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL30182423 0.79 MAPT (0.69) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL6942730 0.79 GAA (0.69) NAMPTMAPTSMN1; SMN2MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093624-B2 NAMPT and ROCK inhibitors ABBVIE INC. (US) 2018-10-09 US disclosed
US-9302989-B2 NAMPT and rock inhibitors ABBVIE INC. (US) 2016-04-05 US disclosed
US-20160031880-A1 Nampt and Rock Inhibitors ABBVIE INC. (US) 2016-02-04 US disclosed
US-20120122842-A1 NAMPT AND ROCK INHIBITORS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093624-B2 NAMPT and ROCK inhibitors NAMPT, NNMT, NADK NAMPT 1/4885MAPT 386/4885SMN1; SMN2 1778/4885
US-20120122842-A1 NAMPT AND ROCK INHIBITORS NAMPT, NNMT, NME2 NAMPT 1/4885MAPT 512/4885SMN1; SMN2 917/4885
US-20160031880-A1 Nampt and Rock Inhibitors NAMPT, NNMT, NME2 NAMPT 1/4885MAPT 512/4885SMN1; SMN2 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.